Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II biomarker validation study of first-line biweekly cetuximab plus chemotherapy in KRAS wild-type advanced or metastatic colorectal cancer
2010-019236-12Phase 2Completed
- Sponsor
- GEMCAD
- Start
- Jul 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, oxaliplatin, irinotecan, folinic acid and fluorouracil in colorectal cancer (CRC), sponsored by GEMCAD. Started Jul 2010; status: completed.
02
Drugs
cetuximaboxaliplatinirinotecanfolinic acidfluorouracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2010-019236-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019236-12.